Target intelligence / Profile preview

ATP-dependent RNA helicase DHX30 (DHX30)

Target
DHX30
Molecular classification
Enzyme, RNA helicase, DEAH box polypeptide family
01

Overview

ATP-dependent RNA helicase DHX30 is a member of the DExH-box family of RNA helicases, enzymes that use ATP hydrolysis to unwind RNA secondary structures[3][2]. It is involved in multiple aspects of RNA metabolism, including translation initiation, nuclear and mitochondrial splicing, ribosome and spliceosome assembly, and the regulation of RNA-protein complexes (RNPs)[2][3][1]. DHX30 modulates translation in neurons and is essential for stress granule formation; dysfunction of this enzyme impairs global protein synthesis and triggers pathological stress responses in cells[1][3]. Mutations in DHX30 have been associated with severe neurodevelopmental disorders, manifesting as global developmental delay, intellectual disability, severe speech impairment, and gait abnormalities[2][3]. In antiviral defense, DHX30 interacts with the zinc-finger antiviral protein to promote the degradation of viral RNAs and can influence viral infectivity, including the response to HIV-1[2]. It also acts as a transcriptional repressor in retinal development[2]. Overall, DHX30 plays critical roles in neuronal development, cellular stress responses, and host antiviral mechanisms[2][1][3].

Other names
DExH-box helicase 30DDX30KIAA0890FLJ11214DEAH box protein 30NEDMIALRETCORretina co-repressor
02

Biological functions

RNA metabolismRNA unwindingTranslation regulationStress granule formationMitochondrial DNA/RNA processingAntiviral responseTranscriptional repression in retinal development
03

Disease associations

Neurodevelopmental disorderGlobal developmental delayIntellectual disabilitySpeech impairmentGait abnormalitiesViral infection
04

Safety considerations

Potential for global translation inhibitionImpaired neuronal functionFormation of stress granules leading to neurodevelopmental impairment
05

Biomarkers

Missense mutations in DHX30 (mutational analysis—especially for neurodevelopmental disorder risk)

Beyond the preview

Go deeper on ATP-dependent RNA helicase DHX30 (DHX30).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ATP-dependent RNA helicase DHX30 (DHX30).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call